Compare MakeMyTrip Ltd (MMYT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? MakeMyTrip Ltd trades at $44.73 (market cap $4.09B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.2× MakeMyTrip Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MMYT | VRTX | |
|---|---|---|
Market Cap | $4.09B | $127.55B |
Volume | 1,828,010 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.25 | $557.96 |
52-Week Low | $36.30 | $407.37 |
Typical Hold Time | 12 Days | 120 Days |
Enterprise Value | $4.75B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $43.53, up 0.28% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported mixed quarterly earnings, with a Q1 2026 beat and Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, but net income margin compressed to 3.23% in 2026. Analyst consensus is strongly bullish with a $77.00 price target, though institutional selling has been noted recently.
The outlook is bifurcated: strong analyst support and a potential Indian listing offer upside, but declining profitability, high P/E ratio, and bearish technicals pose risks. Investors face volatility from operational execution and travel industry cyclicality against a backdrop of Wall Street optimism.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
